EXCLUSIVE: DEA-Licensed Cannabis Co. Maridose To Launch Series A Funding Round At Upcoming Benzinga Conference

Comments
Loading...

Maridose LLC, a company recognized for its contributions to the field of legalized medical cannabis research and product development, and one of the select few companies to have been granted a license by the U.S. Drug Enforcement Administration (DEA) to legally produce cannabis for research purposes, will be launching its Series A funding round at the upcoming Benzinga Cannabis Capital Conference, set to take place on April 16 - 17, 2024, at the Diplomat Beach Resort in Hollywood, Florida,

This development marks a significant shift in the landscape of cannabis research in the United States, which has been tightly regulated since 1968, with the University of Mississippi being the sole producer of legal cannabis for research. Maridose’s entry into this space signifies the end of this monopoly and the beginning of new opportunities for commercial product development and private investment in cannabis research.

Leading the scientific charge at Maridose is Prof. Lumír Ondřej Hanuš, a renowned figure in cannabis research known for isolating Anandamide, the first known endocannabinoid. His partnership with the late Dr. Raphael Mechoulam, known for discovering THC, has produced significant advancements in the understanding of cannabis and its potential therapeutic benefits. “Our DEA license provides a federally legal pathway for Maridose to partner with research organizations and companies,” Richard Shain, founder of Maridose, told Benzinga. He added, “We are excited that Prof. Hanuš’s immense knowledge is now available to researchers working with Maridose,” highlighting the potential impact on patient care both in the U.S. and globally.

To facilitate its Series A funding efforts, Maridose has engaged Young America Capital, signaling its readiness to attract investors and strategic partners interested in advancing the science and commercial development of cannabis.

As Maridose prepares to take the stage at the Benzinga Cannabis Capital Conference, its announcement not only underscores the evolving dynamics of cannabis research and investment but also sets the stage for potential breakthroughs in medical cannabis.

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!

Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.